Using the national electronic prescription system to determine the primary non-adherence to medication in the Czech Republic.
eHealth
electronic prescribing
filling prescription
medication adherence
primary medication non-adherence
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
12
2022
accepted:
13
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
The primary medication non-adherence occurs when a patient does not collect his or her newly prescribed medication. Various studies give estimates that this occurs between 0.2 percent and 74 percent. Recently, this topic has been researched by analyzing data in national electronic prescription systems. The database of the Czech electronic prescription system was used to obtain the number of all prescriptions issued and collected in 2021 for fifty particular substances (associated with six medication groups). Additionally, a similar query was performed with an additional criterion that the same substance had not been prescribed within the last 365 days. The data were obtained separately in five age categories. The total number of prescriptions analyzed in this study was over 21 million, which represents almost 30 percent of all prescriptions issued in the Czech Republic in 2021. The primary medication non-adherence in the selected substances was 4.56 percent, which negatively correlates (rxy = 0.707) with the age of a patient. There is a higher primary non-adherence in the Psychoanaleptics and Lipid modifying medication groups than in the whole studied sample (
Identifiants
pubmed: 37033608
doi: 10.3389/fphar.2023.1128457
pii: 1128457
pmc: PMC10073447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1128457Informations de copyright
Copyright © 2023 Bruthans, Berger, Šoltés and Michálek.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
J Gen Intern Med. 2012 Jan;27(1):57-64
pubmed: 21879374
Front Pharmacol. 2019 Oct 31;10:1280
pubmed: 31736757
Res Social Adm Pharm. 2018 Aug;14(8):776-783
pubmed: 29030133
J Gen Intern Med. 2010 Apr;25(4):284-90
pubmed: 20131023
Int J Clin Pract. 2019 Jun;73(6):e13350
pubmed: 30941854
Int J Med Inform. 2019 Mar;123:49-53
pubmed: 30654903
Front Pharmacol. 2020 May 21;11:783
pubmed: 32528297
Int J Med Inform. 2020 Sep;141:104205
pubmed: 32492586
J Manag Care Spec Pharm. 2018 May;24(5):440-448
pubmed: 29694286
J Gen Intern Med. 2013 Sep;28(9):1181-7
pubmed: 23512335
Br J Clin Pharmacol. 2017 Jun;83(6):1328-1340
pubmed: 28229476
Med Care. 2013 Aug;51(8 Suppl 3):S11-21
pubmed: 23774515
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
J Am Acad Dermatol. 2017 Jun;76(6):1193-1195
pubmed: 28522045
Health Serv Res. 2009 Oct;44(5 Pt 1):1640-61
pubmed: 19500161
JAMA Intern Med. 2017 Mar 1;177(3):371-379
pubmed: 28114642
Int J Clin Pharm. 2015 Aug;37(4):626-35
pubmed: 25832675
Int J Qual Health Care. 2007 Jun;19(3):134-40
pubmed: 17449480
Pol Arch Intern Med. 2020 Jan 31;130(1):8-16
pubmed: 31559971
J Manag Care Spec Pharm. 2016 May;22(5):516-23
pubmed: 27123913
Res Social Adm Pharm. 2020 Apr;16(4):553-559
pubmed: 31253500
Br J Clin Pharmacol. 2023 Jan;89(1):268-278
pubmed: 35896043
Can Fam Physician. 2022 Jul;68(7):520-527
pubmed: 35831084